Diseases, Conditions, Syndromes

Tailor-made therapy of multi-resistant tuberculosis

Globally, tuberculosis is the most common bacterial infectious disease leading to death. The pathogen causing tuberculosis, Mycobacterium tuberculosis, has a number of peculiarities. One is that it is growing very slowly. ...

Diseases, Conditions, Syndromes

New WHO handbook on systematic screening for active tuberculosis

New World Health Organization (WHO) guidelines and handbook on systematic screening for active tuberculosis were published in March 2021. The handbook cites two studies from Ph.D. students Olivia Biermann's doctoral thesis, ...


Anti-tuberculosis drug can be safely dosed even higher

A considerably higher dose of the anti-tuberculosis drug rifampicin is safe and can also lead to a shorter treatment for tuberculosis and less resistance. This is what researchers from Radboud university medical center in ...


Researchers test a new TB vaccine

A clinical pharmacologist from RUDN University together with his colleagues from Gamaleya Research Institute of Epidemiology and Microbiology completed the second stage of a clinical trial of a new TB vaccine that was conducted ...

Diseases, Conditions, Syndromes

S.Africa trial shows promise for drug-resistant TB regimen

Almost all patients who received a new treatment for highly drug-resistant tuberculosis are still clear of the disease two years after a medical trial in South Africa, findings from a long-term study showed Thursday.


New tuberculosis drug regimen slashes treatment time

Tuberculosis is an age-old respiratory scourge, with a new twist: growing resistance to multiple first- and second-line drugs. UF researchers and physicians report on using a novel treatment to slash treatment timeā€”and ...

page 2 from 40